Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraosseous vs Intravenous Vancomycin in Revision Total Knee Arthroplasty
NCT07283068Not yet recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Jun 2026
- Primary completion
- Feb 2030
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
01
Overview
Randomised, open-label trial of vancomycin in surgical site infection (SSI) (2 arms), sponsored by Houston Methodist Research Institute. Primary endpoint: Level of Vancomycin. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
vancomycin
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT07283068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07283068.